Diabetes is the most common risk factor in inducing hypertension, nephropathy and retinopathy. The bradykinin (BK)-forming system has been proposed to protect cardiovascular and renal functions. We therefore evaluated urinary active and proactive kallikrein, total kininogen, plasma tissue kallikrein, plasma creatinine, plasma glucose and plasma HbAlc in newly diagnosed untreated type 2 diabetic patients and healthy subjects. In diabetic patients, urinary and plasma tissue kallikrein concentrations were significantly increased. In addition, plasma prekallikrein levels were also significantly higher. However, urinary kininogen values were significantly reduced in diabetic patients when compared with healthy subjects. This is the first investigation among Kuwaiti Arab patients with type 2 diabetes showing abnormal activities in the BK-forming system. High levels of plasma prekallikrein may be a risk factor for developing high blood pressure as well as nephropathy. The urinary and plasma tissue kallikrein concentrations were higher in diabetic patients, which could indicate the hyperactivities of these components, and may result in increased levels of plasma glucose to induce diabetes. Furthermore, the urinary kininogen levels were reduced in diabetic patients. These alterations might reflect the utilization of urinary kininogen to form BK, a potent inflammatory agent. However, this hypothesis needs further investigation.
Diabetes is a major risk factor in the development of cardiovascular and renal complications. Previous studies have indicated conflicting results of the bradykinin-forming components (l) in diabetic patients and experimental animals. High prevalence rates (20-25%) of type 2 diabetes have been documented in the Kuwaiti population (2, 3) . Type2 diabetes can lead to hypertension, renal and cardiac complications, resulting in high rates of mortality worldwide. Bradykinin (BK), a pharmacologically active polypeptide, is one of the kinins which is released in the tissues and body fluids as a result of enzymatic action of kallikreins on kininogens. The two types of kallikrein are tissue kallikrein and plasma kallikrein. Plasma kallikrein is also present in inactive form known as prekallikrein, which can be activated into kallikrein. Tissue kallikrein is mainly expressed in the kidney (urine), glandular tissue, vasculature (4), heart and brain. It preferentially acts on low molecular weight kininogen substrate to release lysyl-BK. Tissue kallikrein has also been reported to be present in plasma (5, 6) . Plasma kallikrein preferentially acts on high molecular weight kininogen substrate to release BK. BK promotes both cardiovascular and renal functions, for example, vasodilation, natriuresis and diuresis (7, 8) . BK is rapidly « 15 sec) inactivated by circulating kinases (9) . BK acts on Bl receptor (BIR) and B2 receptor (B2R) (10) to elicit physiological and pharmacological actions. It has been shown previously that type 1 diabetic patients are at a risk of developing nephropathy with increased renal tissue kallikrein and BK levels (11). In addition, raised plasma prekallikrein levels in type 1 diabetes has been considered as a risk marker for hypertension and nephropathy (12) . This has not yet been reported in type 2 diabetic patients. However, in diabetic rats, it has been shown that moderate hyperglycemia, in association with increased urinary kallikrein excretion, can result in reduced renal vascular resistance (RVR) and an increase in both renal plasma flow (RPF) and glomerular filtration rate (GFR) (11, 12) . The treatment with aprotinin, a kallikrein inhibitor, to these rats increased the RVR and reduced the GFR and RPF (11, 12). However, there has been no investigation on the BK-forming components in type 2 diabetes with special reference to the Kuwaiti Arab population. Hence, we aimed at investigating the BK-forming components, plasma prekallikrein, urinary and plasma tissue kallikrein and urinary kininogen levels in Kuwaiti type 2 diabetic patients. These patients were newly diagnosed and had received no prior anti-diabetic treatment.
MATERIALS AND METHODS

Patients and healthy subjects
The participants in this study included: SIX type 2 diabetic patients (I male and 5 females; aged 27-45 years, mean±SEM = 36.3±1.5 years) and eighteen healthy subjects (8 males and 10 females, aged 25-43 years, mean±SEM = 30.3±2.1 years). The females were in premenopausal state. The study was approved by the ethical committees of the Health Sciences Centre and the Kuwait Ministry of Health. Written consents were obtained from all the subjects before their inclusion in the study. The diabetics were all freshly diagnosed cases with no previous treatment. The non-diabetic, healthy subjects were clinically examined and underwent laboratory tests to rule out hypertension, diabetes and other co-morbid conditions. Diabetic patients and healthy subjects were instructed to fast for 10-12 hours but were asked to drink enough water before the blood sampling and morning urine collection.
Sample collection and storage
Twenty ml of peripheral blood samples were collected from the patients and healthy subjects in appropriate BD vacutainertubes (containing 3.8% sodium citrate, ethylene diamine tetra acetic acid (EDTA) and clot activator and gel), and around 10 ml of midstream urine was collected in sterile containers to estimate the kallikrein and kininogen. Ten ml of the blood sample was used for clinical analysis to measure glucose, glycosylated hemoglobin (HbAlc) and plasma creatinine. The remaining blood samples were used to estimate the prekallikrein and kal1ikrein levels. The collected blood was immediately centrifuged at 1000 rpm for 15 min at 4°C. Aliquots of the obtained plasma were stored at -80°C. Ten ml of urine were centrifuged for 30 min at 1000 rpm at 4°C and aliquots were stored at -80°C.
Glucose and HbA Ic measurements
Aliquots of the collected fasting blood samples were used for the measurement of the plasma glucose levels by means of the oxygen rate method employing a Beckman Coulter Oxygen Electrode (glucose oxidase method, Beckman Coulter Inc, Galway, Ireland). The HbAlc was measured by the Beckman Synchron LX system (Bechman Instrument Inc, Fullerton, CA 92834-3100) which utilizes two cartridges, HB and Al c to determine A Ic concentration as a percentage of total Hb. The hemoglobin was measured by a colorimetric method and the Al c concentration by a turbidimetric immunoinhibition method (13) . The normal range of the HbAlc in our lab was 4.3-5.9%. Serum creatinine was measured by Kobas Integra 400 (Roche Diagnostics, Basel, Switzerland). The test was performed according to the manufacture's protocol (14) .
Estimation oftotal urinary kininogen
Concentration of total kininogen in urine was estimated using Kininogen Human ELISA kit from Abeam (AB I08876, Cambridge, USA). This assay employs a quantitative sandwich enzyme immunoassay technique in which a polyclonal antibody specific for human kininogen has been precoated onto a 96-well plate. Aliquoted urine samples that had been stored at -80°C were used to run the ELISA. The urine samples were diluted 200 times with a diluent provided with the kit. The optical density of the samples were read at 450 nm using Elisys Uno from Human Diagnostics (Germany). The values obtained were multiplied by the dilution factor. The concentration of kininogen in urine is expressed in ug/ml. 101.J. Immuoopalhol. Pharmacol.
<0.05 was considered as a level of significance.
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Estimation ofplasma prekallikrein (PK)
The concentration of PK in plasma was determined using enzyme linked immunosorbent assay (ELISA) from Uscn Life Science ELISA kits (E91801Hu, Wuhan, China). The plasma samples were diluted 10 times with 0.02 mol/L (pH=7.Q-7.2) phosphate buffered saline (PBS). The steps for ELISA were carried out as per the protocol described in the kit. The optical density (OD) of the samples were read at 450 nm using Elisys Uno from Human Diagnostics, (Germany). The OD values of the sample were read against the standard. The values obtained were multiplied by the dilution factor. The results are expressed in ug/rnl.
Estimation ofurinary andplasma tissue Kallikrein (KLK 1)
The tissue kallikrein levels in the samples were estimated using Uscn Life Science ELISA kits (E90967Hu, Wuhan, China). The kit was a sandwich enzyme immunoassay for in vitro quantitative measurement of KLK I in human serum, plasma and urine. Aliquoted urine and plasma samples which were stored at -80°C were used for the analysis. The preparation of the standard and the experiments were carried out as per the protocol described in the kit. The optical density of the samples were read at 450 nm using Elisys Uno from Human Diagnostics (Germany). The results are presented in pglml.
Analysis ofdata
The parameter values are expressed as mean±S.E.M. Non-parametric Mann-Whitney U-test was applied to determine the significance of differences. A p value of
RESULTS
Clinical data
The patients', as well as healthy volunteers', demographic data and characteristics are presented in Table I . The mean level of fasting plasma glucose levels were significantly (p<O.O 1) raised in diabetic patients (8.1±1.08 mmol/L) in contrast to the controls (4.7±0.28 mmol/L). This obviously confirmed the presence of type 2 diabetes. Similarly, the mean HbA1c (%) concentration was found to be significantly higher (p<0.05) in diabetic patients (6.98±1.09%) in comparison to the control subjects (5.26±0.41%). In addition, there was a significant difference (p<0.05) in the body mass index (BMI) between the healthy subjects (27.9±1.3) and the diabetic patients (35.3±1.7). The mean plasma creatinine levels between the diabetic patients (58.33±11.75umol/L) and healthy subjects (58.38±13.30 umol/L) did not differ significantly (p>0.05).
Bradykinin-forming components
There was no significant difference (p>0.05) in the mean total urinary kininogen level between the healthy male (6.8±1.2 ug/ml) and female (5.9±0.9 ug/ml) subjects. However, the mean urinary kininogen level was significantly higher (p<0.05) in healthy subjects (6.32±O.70 ug/ml) compared to diabetic patients (3.l6±O.68 ug/ml) (Fig. la) . The mean plasma prekallikrein level was significantly increased (p<O.O I) in diabetic patients (O.58±O.03 ug/ml) compared to healthy subjects (0.43±O.02 ug/ ml) (Fig. Ib) . The mean urinary tissue kallikrein level was found to be lower (P<O.05) in healthy subjects (l4.4±1.9 pg/ml) than that in diabetic patients (39.8±10.2 pglml) ( Fig. 2a) . Moreover, the mean plasma tissue kallikrein level was significantly increased (P<O.Ol) in diabetic patients (40.4±10.2 pglml) compared to the control subjects (15.30±0.77 pg/ml) ( Fig. 2b ).
DISCUSSION
The present study represents the first attempt to investigate the role of the BK-forming components in Kuwaiti patients recently diagnosed as type 2 diabetics during their first visit to the outpatient clinics and who had not taken any prior medication. These patients had elevated fasting blood glucose, BMI and HbAlc levels. However, their creatinine levels were within the normal limits. The sample size ofthe newly diagnosed type 2 diabetics was small due to the challenges in recruiting participants without prior treatment (particularly in our secondary service hospital, Mubarak Al-Kabeer Hospital), as most of the patients had started the anti-diabetic therapy prior to visiting the outpatient clinic due to ethical considerations as they could not be left untreated due to their hyperglycemic state. Therefore, the diabetic group in our study was a small group of mild type 2 diabetics.
The contribution of the renal BK-forming components has been implicated in renal injury (12) in experimental and type 1 diabetes. The urinary and plasma BK-forming components are comprised of proteins that mediate their effects on vasculature by releasing BK (12, 15, 16) . It is also known that the tissue kallikrein present in the urine originates from the kidney and it reflects the renal activity of BK (9) . The present investigation demonstrated, for the first time, that urinary tissue kallikrein levels were significantly increased in untreated type 2 diabetic patients. In this regard, previous investigations have reported high levels of urinary tissue kallikrein and BK production, in association with RVR, GFR and RPF (11, 12) in diabetic rats. Acute administration of aprotinin, a kallikrein inhibitor, and/or B2R antagonist in these hyperfiltering diabetic rats reduced the GFR and RPF (11, 12) . These findings may suggest that the high levels of renal tissue kallikrein and BK may mediate renal hyperfiltration in diabetes. There was no alteration in the creatinine levels in the present study, albeit high plasma prekallikrein levels may suggest the onset of renal abnormalities. In fact, high plasma prekallikrein levels have been reported in type 1 but not in type 2 diabetic patients (10) . These investigators suggested that increased plasma prekallikrein level could be a risk factor for hypertension and nephropathy in type 1 diabetes. The present study may also suggest a similar mechanism for developing hypertension and nephropathy in type 2 diabetic patients. Therefore, plasma prekallikrein could be a useful marker for monitoring diabetic patients for developing hypertension and/or renal abnormalities.
It is of interest to suggest that the early detection of type 2 diabetes based on high urinary kallikrein could be an indicator for future renal abnormality that can be prevented by anti-diabetic treatment. In addition, high plasma prekallikrein activity may serve as an indicator for causing hypertension and left ventricular hypertrophy in diabetic rats (17) . A similar finding can be extrapolated to type 2 diabetic patients such as in the present study. On the other hand, we observed reduced levels of total urinary kininogen in type 2 diabetic patients. This observation might be a reflection on the utilization of kininogen to form BK, a proinflammatory agent as previously reported (18, 19) . In this regard, it has been suggested that BKlR and BK2R antagonists may normalize the diabetic state in experimentallyinduced diabetes in mice (20) . Thus, BK antagonist may be targeted for future use in diabetic disorders. Moreover, high levels of tissue kallikrein could diminish glucose transport to the tissue (21) . This may also suggest that high levels of tissue kallikrein in diabetic patients might be a predisposing factor in the induction of type 2 diabetes due to the inhibition of glucose transfer to the tissues (21) . Plasma levels oftissue kallikrein have been reported to be increased in type 2 diabetes, as previously reported (22) . In the present study however, we also observed high concentrations of plasma tissue kallikrein, which presumably may be due to the hyperactivity of the BK-forming system to induce systemic metabolic abnormalities. It is noteworthy to state that tissue kallikrein may activate B2R directly without BK generation in the development of diabetes (23) . Furthermore, diabetic rats have been shown to have the glomerular B1Rand B2R expression in the diabetic state (24) .
A continuation of the resent study is currently in progress to evaluate the influence ofdiabetic treatment on BK-forming components in larger samples. These results may provide support to BK-forming components as an extra criterion in the early diagnosis of diabetic risk factors in predicting and preventing nephropathy and retinopathy caused by diabetes.
